


Amendments to the Specification:


Please replace the paragraphs at page 5, line 26 - page 6, line 25 with the following rewritten paragraphs:

C' The process for the preparation of compounds of the formula I according to Claim 1, (1H-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone being excluded, is characterized in that

a) a compound of the formula II




in which L is Cl, Br, I or a free or reactively functionally modified OH group, and R<sup>4</sup> and R<sup>5</sup> have the meaning indicated in formula I Claim 1, is reacted with a compound of the formula III




in which R<sup>1</sup> has the meaning indicated in formula I Claim 1,

or

b) a compound of the formula IV



in which  $R^4$  and  $R^5$  have the meaning indicated in formula I Claim 1,  
is reacted with a compound of the formula V



in which L is Cl, Br, I or a free or reactively functionally modified OH group, and  $R^1$  has the meaning indicated in formula I Claim 1,

or

c) if appropriate, one of the radicals  $R^1$ ,  $R^4$  and/or  $R^5$  is converted into another radical  $R^1$ ,  $R^4$  and/or  $R^5$  by cleaving, for example, an OA group with formation of an OH group and/or converting a CHO group into a CN group,

and/or a base of the formula I which is obtained is converted into one of its salts by treating with an acid.

The invention also relates to the compounds of the formula I ~~according to Claim 1~~, and to their physiologically acceptable salts and solvates as medicaments, (1H-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone being excluded.

The invention relates in particular to the compounds of the formula I ~~according to Claim 1~~, and to their physiologically acceptable salts and solvates as medicaments having 5-HT<sub>2A</sub> receptor-

C1 antagonistic action.

Please replace the paragraph at page 19, lines 5-15 with the following rewritten paragraph:

C2  
(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 250°;  
(1*H*-indol-4-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-4-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone, hydrochloride,  
m.p. 166-168°;

Please replace the paragraph at page 19, lines 17-29 with the following rewritten paragraph:

(1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone,  
(1*H*-indol-5-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-5-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-5-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,  
(1*H*-indol-5-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone,  
(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p.  
240.9°;

Please replace the paragraph at page 19, line 31- page 20, line 9 with the following rewritten paragraph:

C3  
(1*H*-indol-6-yl)-[4-phenethylpiperazin-1-yl]methanone,  
(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 284.0-  
284.4°;

(1*H*-indol-6-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 204.2-205.7°;

(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 251.0-252.5°;

(1*H*-indol-6-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,

(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 240-241°;

Please replace the paragraph at page 20, lines 17-34 with the following rewritten paragraph:

(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride, m.p. 221°;

(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 274°;

(1*H*-indol-7-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone,

(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 251.0-252.5°;

(1*H*-indol-7-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,

(1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone,

(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 287°;

(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. >300°;

Please replace the paragraph at page 20, line 36 - page 21, line 8 with the following rewritten paragraph:

(2,3-dimethyl-1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone,

(2,3-dimethyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, 86.5-89°;

(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone,

C<sup>5</sup>  
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone,  
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,  
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone,

Please replace the paragraph at page 21, lines 10-22 with the following rewritten paragraph:

C<sup>6</sup>  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride, m.p. 235-237°;  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone,  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-2-ylethyl)piperazin-1-yl]methanone,  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone,  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-3-ylethyl)piperazin-1-yl]methanone,  
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(2,5-dichlorothiophen-3-ylethyl)piperazin-1-yl]methanone.

Please replace the paragraph at page 21, line 24 - page 22, line 22 with the following rewritten paragraph:

C<sup>7</sup>  
(3-formyl-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 279.3°;  
(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 257.5 - 259.0°;  
(1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 266 - 267°;  
(3-cyano-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 210°;  
(3-cyano-1*H*-indol-7-yl)-[4-(naphth-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 284.0 - 285.5°;

(3-cyano-1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 284.0 - 285.5°;

(3-cyano-1*H*-indol-4-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 213 - 215.5°;

(3-cyano-1*H*-indol-7-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 212.5 - 214°;

(3-aminocarbonyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 280 - 281°;

(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, methanesulfonate, m.p. 212.5 - 214°;

(3-cyano-1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-ylethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 301.5 - 303.0°;

(3-cyano-1*H*-indol-7-yl)-(4-phenethyl-piperazin-1-yl)methanone, methanesulfonate, m.p. 294.7 - 297°;

(3-cyano-1*H*-indol-7-yl)-[4-(2,4-difluorophenethyl)piperazin-1-yl]methanone, hydrochloride, m.p. 295.6 - 297.0°;

7-{4-[2-(4-fluorophenyl)ethyl]piperazin-1-carbonyl}-1*H*-indole-2,3-dione.

---